WP1066 with radiation for people newly diagnosed with glioblastoma
Official title: WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether adding a drug called WP1066 to radiation helps people with a new glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary diagnosis.
Read our full plain-language summary
What the trial team says
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.
Key facts
- Registry number
- NCT05879250
- Stage of testing
- Phase 2
- Conditions studied
- Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Where it is running
This trial lists 2 sites.
-
Illinois
- Northwestern University (Chicago)
- Northwestern Medicine: Warrenville (Warrenville)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.